Aspergillus nidulans

A putative ABC transporter gene, CcT1, is involved in beauvericin synthesis, conidiation, and oxidative stress resistance in Cordyceps chanhua

mycolabadmin

Cordyceps chanhua is a medicinal fungus used in traditional Chinese medicine that produces a compound called beauvericin, which has health benefits but can be toxic in high amounts. Researchers discovered a gene called CcT1 that controls how much beauvericin the fungus makes. By removing this gene, they could reduce beauvericin production by 64%, making the fungus safer to use as medicine while maintaining other beneficial properties.

A Comprehensive Review of the Diversity of Fungal Secondary Metabolites and Their Emerging Applications in Healthcare and Environment

mycolabadmin

Fungi naturally produce complex chemical compounds called secondary metabolites that have powerful effects against diseases and pests. These include well-known medicines like penicillin and compounds that can fight cancer, reduce inflammation, and lower cholesterol. Scientists are now using advanced genetic and biotechnology techniques to increase production of these fungal compounds, making them more available and affordable for medical, agricultural, and environmental applications. This research shows how fungi could be important sources of new medicines and sustainable alternatives to synthetic chemicals.

Fungal Drug Discovery for Chronic Disease: History, New Discoveries and New Approaches

mycolabadmin

This article examines how fungi have provided humanity with some of the most important medicines ever created, including penicillin, drugs that prevent organ rejection, and cholesterol-lowering statins. Many of these fungal compounds work as medicines because they target processes that are similar in both fungi and humans, helping them survive competition with other fungi while coincidentally treating human diseases. New researchers are now using modern genetic tools to discover additional fungal medicines, with several promising candidates currently being tested in clinical trials for cancer, depression, and other chronic diseases.

Resolving the fungal velvet domain architecture by Aspergillus nidulans VelB

mycolabadmin

Scientists studied how fungi use special proteins called velvet regulators to control their growth and produce protective chemicals. By examining these proteins in different fungi and using genetic techniques, they found that two specific amino acids are critical for these proteins to interact with each other. This discovery helps explain how fungi coordinate their development with the production of important chemicals, which could eventually help control harmful fungi or improve industrial fungal applications.

Fungal Infections – a Stealthy Enemy in Patients with Chronic Granulomatous Disease: a 28-years’ Experience from North India

mycolabadmin

Patients with chronic granulomatous disease (CGD), a rare immune system disorder, are highly susceptible to serious fungal infections. This study of 99 patients over 28 years found that 40% developed fungal infections, mostly caused by Aspergillus fungi affecting the lungs. These infections were life-threatening, with over half the infected patients dying despite aggressive treatment with antifungal medications. Doctors need to screen for fungal infections early, even in patients without obvious symptoms, and treat infants and males more aggressively.

Detection of electrical signals in fungal mycelia in response to external stimuli

mycolabadmin

Scientists developed a new tool to detect electrical signals produced by fungal mycelia, the root-like networks of fungi. Using special circuit boards with tiny sensors and a noise-reducing cage, they successfully measured electrical activity in growing fungi that varied when exposed to toxic chemicals. These findings suggest fungi use electrical signals to communicate within their networks, similar to how nerve cells communicate in animals.

Convergent evolution links molybdenum insertase domains with organism-specific sequences

mycolabadmin

Scientists studied how fungi use a special protein called Mo insertase to create molybdenum cofactor, which is essential for life. By testing different versions of this protein from various organisms, they discovered that fungi have developed a unique version with a special 20-amino acid region that cannot be replaced with versions from plants or animals. This finding shows that evolution has fine-tuned this protein differently in different organisms.

New bioactive secondary metabolites from fungi: 2024

mycolabadmin

Scientists discovered 907 new compounds from fungi in 2024, with most being terpenoids and polyketides that show promise as medicines. These fungal compounds demonstrate strong activity against bacteria, fungi, and inflammation, with some showing potential against cancer and diabetes. The research uses advanced techniques like genome mining and metabolomics to find these compounds more efficiently. This accelerating discovery rate suggests fungi could be a major source for developing new drugs to treat various diseases.

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

This study compared the chemical makeup of psilocybin mushroom mycelium (the root-like growth) versus fruiting bodies (the mushrooms themselves) to understand their different therapeutic potential. While fruiting bodies contain much higher levels of psilocybin, the psychoactive compound, mycelium accumulates other beneficial compounds like α-GPC that may enhance cognition and motor function without strong psychedelic effects. This research suggests that mushroom mycelium could be developed as a non-intoxicating therapeutic alternative with its own unique health benefits.

Appearance of Environment-Linked Azole Resistance in the Aspergillus fumigatus Complex in New Zealand

mycolabadmin

Researchers in New Zealand have discovered that a dangerous fungus called Aspergillus fumigatus is developing resistance to commonly used antifungal medications. Unlike previous cases where the resistance came from medical treatment, this new resistance appears to come from environmental exposure, possibly through garden fungicides that people can buy at garden centers. The study found that people, especially lung transplant patients, may be acquiring these resistant fungal strains from their surroundings rather than from hospitals, highlighting the need for better monitoring of agricultural fungicide use.

Fungal Species: Aspergillus nidulans